Skip to content

Rainer Krähenmann

5 papers in the library · 265 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Esketamine for treatment-resistant depression: Comparing two maintenance schedules in an observational real-world study

Research Square July 9, 2026 Samuel Westenhöfer, Yamina Ehrt, Barbora Provaznikova et al.

Abstract Background : Treatment-resistant depression (TRD) is associated with substantial clinical and socioeconomic burden. Intranasal esketamine has shown efficacy for TRD in clinical trials and real-world studies. However, evidence on optimal maintenance scheduling is limited. We therefore investigated whether two maintenance schedules differing in their inter-dose intervals were associated...

Lower-dose psycholytic therapy – A neglected approach

Frontiers in Psychiatry December 2, 2022 Torsten Passie, Jeffrey Guss, Rainer Krähenmann 71 citations

Lysergic acid diethylamide (LSD) and similar psychoactive drugs have been used in psychotherapy since 1949, when the first clinical study with lower-dose LSD showed therapeutically relevant effects. This caused an intense interest among psychotherapists and researchers, alike, on an international scale. In 1960, the use of serial lower-dose LSD/psilocybin sessions in a psychoanalytical...

The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making

European Psychiatry March 1, 2015 Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al. 20 citations

Social cognition is a crucial factor influencing development, progress, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. In particular, patients suffering from depression show an increased negative reaction to social exclusion and deficits in empathy. The 5HT-1A/2A receptor agonist psilocybin has previously...

Acute ketamine administration modulates glutamatergic neurotransmission and functional brain activation in prefrontal cortex implications for major depression

Pharmacopsychiatry September 1, 2011 Milan Scheidegger, Anke Henning, Martin Walter et al.

Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at subanaesthetic doses. This multimodal imaging study reveals the effects of a subanaesthetic ketamine infusion on fMRI-BOLD responses during an emotional processing task and their relationship to glutamatergic metabolite concentrations in the pregenual anterior cingulate cortex (PACC) assessed by...